EGLN2
Prolyl hydroxylase EGLN2
As of the edition of 20 October 2026, EGLN2 (prolyl hydroxylase EGLN2, UniProt Q96KS0) has 3 drugs tested at it and 8 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96KS0
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 1
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones; Infections; Lungs and airways; Nervous system
- Registered trials of its drugs
- 145
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Roxadustat | Marketed | Phase 4 | none listed |
| Daprodustat | Marketed | Phase 4 | Ends 2038 |
| Vadadustat | Marketed | Phase 4 | Ends 2034 |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| GSK | Route B |
| Akebia Therapeutics | Route B |
| Medice Arzneimittel Pütter | Route B |
The other 5 companies at EGLN2
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at EGLN2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.